Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. - Wikidata - awgldk - TriplyDB

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.

http://www.wikidata.org/entity/Q36609778

about

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia Overview of prescription omega-3 fatty acid products for hypertriglyceridemia Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.Red blood cell fatty acids and biomarkers of inflammation: a cross-sectional study in a community-based cohort.Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents.Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)Icosapent ethyl for the treatment of hypertriglyceridemia.Icosapent ethyl: a review of its use in severe hypertriglyceridemia.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids.Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review.Nutraceuticals as therapeutic agents for atherosclerosis.Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.

P2860

Q26738554-7B5F86BD-A93D-4131-B361-2632336A4902 Q26752919-FB79E9BA-0E9E-4E77-9348-28C5D79EBE32 Q28076399-8C950F5F-D607-45F9-A17A-2904D52C2D40 Q28251391-C2D515B3-33F3-47E3-819E-07A0A6DCBE61 Q33578422-7E66AA6C-F721-4A73-93A9-5B3A597043DB Q35879822-BB779792-D3A3-4CAC-969F-2178EB5BE97B Q36712679-3FECF4C8-E19A-414E-82AB-7AD726CC07BB Q37074239-A9EA8D16-014D-4404-82E7-AAC05117835F Q37615904-8D408340-B534-4539-8345-FFFA4F237DAC Q38108834-606BD3CD-BE5E-4054-817F-B3A266CCC846 Q38271868-E3F353A4-65A2-40A5-A5BA-345D980681A8 Q38546242-46DFB6E8-5E66-4B6D-8941-E0518766E53A Q38882294-A6012B7D-0F03-46DA-A913-92B6FD573053 Q46962453-E77F7276-BD62-4C14-B8E0-23D9B3D6E5C4 Q47633216-7B86F013-3919-4BC9-A55E-184D0732C9BB Q48173359-5AAD4E7D-73B6-4FE4-9A42-4639E69B129A Q49266738-34CCBDC8-7D34-4528-8B81-FD8B1C8D7138 Q49904156-A9770985-D2F1-4ED3-BF47-E1DD2E6845B7 Q51734047-85B1F9E7-8866-4773-A3A0-564E7BCCFCA4 Q53664867-A602368D-06CF-483B-B1BE-919DD0ECA722

P2860

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.

http://www.wikidata.org/entity/Q36609778

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Icosapent ethyl, a pure ethyl ...... the MARINE and ANCHOR studies.

@ast

Icosapent ethyl, a pure ethyl ...... the MARINE and ANCHOR studies.

@en

type

label

Icosapent ethyl, a pure ethyl ...... the MARINE and ANCHOR studies.

@ast

Icosapent ethyl, a pure ethyl ...... the MARINE and ANCHOR studies.

@en

prefLabel

Icosapent ethyl, a pure ethyl ...... the MARINE and ANCHOR studies.

@ast

Icosapent ethyl, a pure ethyl ...... the MARINE and ANCHOR studies.

@en

P1433

Q36609778-8E8C7499-545B-4CDD-925F-95FA8B577035

P1476

Q36609778-1465B948-025B-4140-AC16-802FB293C536

P2093

Q36609778-7451A689-D2EC-48D7-A39C-143CC5459E55

Q36609778-9B814C3B-E379-46E9-B32A-93410FDE274E

Q36609778-A1BF14E3-64EA-4A72-AC57-F244F0F3236A

Q36609778-B7CFF4F2-A346-431B-9B6B-E3B88BF3662B

Q36609778-FDF4B663-EE57-4841-8F2D-8EFBAA9F7911

P2860

Q36609778-05E8478B-10F5-4CD2-893C-435C444CCA21

Q36609778-1D00C6AD-466B-45A0-B0C0-0AF4D8711A81

Q36609778-1D0C641C-15DE-4714-B02E-56EFA5F60B33

Q36609778-2519E07B-014F-48D3-A591-2F493F37804E

Q36609778-2D83695F-FB37-4537-85F8-B603ECD466C6

Q36609778-3068477B-2436-40DE-B8A2-FFDC2D154D4D

Q36609778-306A35E6-1A7F-48BB-BA00-18EE97468C16

Q36609778-39018891-B4C5-4222-95B8-BE4AE650C906

Q36609778-4B76C420-B234-4B8C-9D6C-0B6D64A81342

Q36609778-5262089A-61FC-48A4-9E21-62CA4C64F36B

P2888

Q36609778-EC476201-5C5E-44C2-81BE-3D3A358AAFB7

P304

Q36609778-0FEBA161-A646-4F17-A744-AAA63193B555

P31

Q36609778-87FD0478-6A33-4AD9-9588-89068C9C0250

P356

Q36609778-BC8BCB13-9F3E-4BFF-B396-9847611CFA1F

P433

Q36609778-969A2482-96B9-46CE-9763-5309AC49AFFB

P478

Q36609778-2E520CC9-11EA-446C-90E0-4701A0E309AE

P577

Q36609778-0DCBD3AD-1401-44EC-9417-F328A8C51468

P5875

Q36609778-1784199B-4E0C-4C8E-B9F6-E0B0C8C2B6D3

P698

Q36609778-703011A2-5B1C-4694-B0E2-74AACD253C1E

P921

Q36609778-9D1CA786-E019-4263-8F75-A44466747B23

P932

Q36609778-F61A0D29-4EE6-4470-893F-6884C0672348

P356

S40256-012-0002-3

P1433

American journal of cardiovascular drugs

P1476

Icosapent ethyl, a pure ethyl ...... the MARINE and ANCHOR studies.

@en

P2093

Christie M Ballantyne

http://www.w3.org/2001/XMLSchema#string

Harold E Bays

http://www.w3.org/2001/XMLSchema#string

Paresh N Soni

http://www.w3.org/2001/XMLSchema#string

Rene A Braeckman

http://www.w3.org/2001/XMLSchema#string

William G Stirtan

http://www.w3.org/2001/XMLSchema#string

P2860

Safety considerations with omega-3 fatty acid therapy

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Atherosclerosis. the road ahead

Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men

Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.

Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.

P2888

s40256-012-0002-3

P304

37-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40256-012-0002-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234158011

http://www.w3.org/2001/XMLSchema#string

P698

23325450

http://www.w3.org/2001/XMLSchema#string

P921

icosapent ethyl

P932

3572383

http://www.w3.org/2001/XMLSchema#string